 |
|
|
| |
9th International Workshop on Clinical Pharmacology of HIV Therapy
The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy
7-9 April 2008
New Orleans
|
| |
| |
Complete slide or poster presentations for some 6th European Resistance Workshop (Budapest, 26-28 March 2008) reports are available via the home page of the meeting organizer, Virology Education
http://www.virology-education.com
http://www.hivpresentation.com/
- The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy - Written by Jennifer J. Kiser, Pharm.D. - (04/22/08)
- 9th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser, Pharm.D. and Courtney V. Fletcher, Pharm.D. (04/22/08)
- Safety, Tolerability and Activity of KP-1461 a Novel Viral Mutagen in HIV Infected Adults - (04/15/08)
- Does HCV or HBV co-infection influence saquinavir exposure in HIV-infected patients without liver function impairment? - (04/14/08)
- The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI - (04/14/08)
- Pharmacokinetic/Pharmacodynamic (PK/PD) analyses for Raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients - (04/14/08)
- The effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral (ARV)-naive HIV-1-infected patients (04/10/08)
- Is Twice-Daily Unboosted Atazanavir 200 mg Worth a Harder Look? (04/10/08)
- Black Race and Drug Interactions Affect Nonnucleoside Levels in TDM Analysis (04/10/08)
- CASTLE Study: Pharmacokinetics and Inhibitory Quotient of Atazanavir/ritonavir 300/100 mg Once Daily Compared to Lopinavir/ritonavir 400/100 mg Twice Daily, Each in Combination with Fixed Dose Tenofovir-Emtricitabine Once Daily, Are Supportive of 48 Week Efficacy and Safety in HIV-1 Infected, Treatment-Naive Subjects (04/10/08)
- Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in Subjects with Hepatic Impairment Compared to Healthy Adult Subjects (04/10/08)
- Effect of Atazanavir with and without Ritonavir on the Pharmacokinetics of the CYP2C8 Probe Rosiglitazone in Healthy Subjects (04/10/08)
- A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients (04/10/08)
- The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours (04/10/08)
- Raltegravir Levels Down With Tipranavir and Up With Atazanavir (04/10/08)
- Once-Daily Darunavir/Ritonavir Keeps Levels High in Healthy Volunteers - written by Mark Mascolini (04/09/08)
- Vicriviroc Troughs Correlate With Response in VICTOR-E1 Salvage Study - written by Mark Mascolini (04/09/08)
- Raltegravir Levels May Drop With Lopinavir/Ritonavir - written by Mark Mascolini (04/09/08)
- Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose Ritonavir (DRV/r) in Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in a Substudy of the GRACE (Gender, Race, and Clinical Experience) Study (04/09/08)
- Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects; tenofovir and HCV affect levels (04/09/08)
- Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (04/09/08)
- Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS) (04/09/08)
- Darunavir and Ritonavir Levels in Black and Hispanic Women - Written by Mark Mascolini (04/08/08)
- Higher Efavirenz Levels--But No More Toxicity--in Nonwhites vs Whites: EuroSIDA - Written by Mark Mascolini (04/08/08)
- Etravirine Levels - Written by Mark Mascolini (04/08/08)
- Tenofovir, Hepatitis, and Weight Moderately Affect Etravirine Levels - Written by Mark Mascolini (04/08/08)
|
|
| |
|
|
|
|
|
|
